•
Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759; SHE: 300759), has announced a comprehensive strategic partnership with the UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN). This collaboration will encompass the entire spectrum of drug development, including small molecules, macromolecules, and gene therapies, from…
•
Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759; SHE: 300759), has announced the sale of its 10.21% stake in Proteologix, a US-based specialist in immune-mediated diseases. The acquisition of Proteologix is set to be completed by healthcare giant Johnson & Johnson (J&J; NYSE:…
•
China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759) has announced plans to invest USD 10.5 million in establishing a joint venture (JV) named Rxilient Biohub Pte. Ltd. in Singapore. This strategic move marks Pharmaron’s expansion into the Southeast Asian market, aiming to provide…
•
China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759) has announced the receipt of a substantial grant from the UK government’s Life Sciences Innovation Manufacturing Fund (LSMIF). The grant will facilitate the expansion of Pharmaron’s existing viral vector and DNA manufacturing facility in Liverpool,…
•
Shanghai-based life science digital supply chain platform Lab Direct has raised USD 10 million in a Series A+ financing round led by Bayland Capital, a joint biomedical fund established by Contract Research Organization (CRO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759) and Legend Capital. The round included participation from…